Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept vs laser for retinopathy of prematurity
ChiCTR2200066940Phase 4Completed
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of conbercept in retinopathy of prematurity (ROP) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Proportion of eyes with inactive retinopathy of prematurity and no structural dysplasia. Started Dec 2022; status: completed.
02
Drugs
conbercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on ChiCTR2200066940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066940.